Mark Erlander, Cardiff Oncology CEO
September 14, 2022 11:33 AM EDTUpdated September 16, 05:19 PM
R&D

Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Aayushi Pratap

News Reporter

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times